Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.

Postgrafting cyclosporine (CSP) given for 35 days resulted in establishment of stable marrow grafts from DLA-identical canine littermates after otherwise suboptimal, but nevertheless, lethal conditioning with 450 cGy of total body irradiation (TBI). We now asked whether sustained allografts could be achieved after sublethal TBI or without TBI. Five groups of recipients were studied. Dogs in group 1 were given 200 cGy TBI and postgrafting CSP, 15 mg/kg twice daily by mouth on days -1 to 35 posttransplant. Dogs in group 2 were given 200 cGy TBI and methotrexate (MTX), 0.4 mg/kg intravenously (I.V.) on days 1, 3, 6, and 11 along with CSP. Dogs in group 3 were given 200 cGy TBI and CSP along with mycophenolate mofetil (MMF), 10 mg/kg twice daily subcutaneously (S.C.) on days 0 to 27 after transplant, a novel immunosuppressive combination. Dogs in group 4 were given 100 cGy TBI and MMF/CSP. Dogs in group 5 were not given TBI and they received MMF/CSP posttransplant. Allografts were assessed by (Ca)n dinucleotide repeat polymorphism studies in cells from peripheral blood, lymph nodes, and marrow. Dogs in group 1 had transient mixed donor-host hematopoietic chimerism for no more than 4 weeks. Three of six dogs in group 2 had transient mixed chimerism for 3 to 11 weeks, and three have remained stable mixed chimeras for up to 60 weeks now. Four of five dogs in group 3 have remained stable mixed chimeras for 54 to 57 weeks now, while one lost the allograft after 12 weeks. All dogs in groups 4 and 5 rejected their allografts after 2 to 12 weeks. In summary, the establishment of stable mixed hematopoietic chimerism following nonmyelosuppressive and nontoxic conditioning programs has remained a difficult goal. Here we present evidence in a large random-bred animal species that this goal may be achievable with pharmacological immunosuppression postgrafting, capable of inhibiting both host-versus-graft (HVG) and graft-versus-host (GVH) reactions in the setting of DLA-identical grafts.

[1]  R. Storb,et al.  Molecular analysis of DLA-DRBB1 polymorphism. , 1996, Tissue antigens.

[2]  E. Ostrander,et al.  Histocompatibility testing of dog families with highly polymorphic microsatellite markers. , 1996, Transplantation.

[3]  J. Scott,et al.  Bone marrow transplantation for sickle cell disease. , 1996, The New England journal of medicine.

[4]  D. Sachs,et al.  Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. , 1996, Transplantation.

[5]  M. Sykes,et al.  Mechanism by which additional monoclonal antibody (mAB) injections overcome the requirement for thymic irradiation to achieve mixed chimerism in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. , 1996, Transplantation.

[6]  M. Sykes,et al.  Natural killer cells weakly resist engraftment of allogeneic, long-term, multilineage-repopulating hematopoietic stem cells. , 1996, Transplantation.

[7]  H. Schlitt,et al.  Development, stability, and clinical correlations of allogeneic microchimerism after solid organ transplantation. , 1996, Transplantation.

[8]  S. Boggs,et al.  Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. , 1996, Journal of immunology.

[9]  H. Gritsch,et al.  Combined simultaneous kidney/bone marrow transplantation. , 1995, Transplantation.

[10]  R. Wiesner,et al.  Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients. , 1995, Transplantation.

[11]  H. Deeg,et al.  DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. , 1995, Blood.

[12]  Y. Colson,et al.  A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. , 1995, Journal of immunology.

[13]  F. Obata,et al.  Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. , 1995, Transplantation proceedings.

[14]  R. Colvin,et al.  Mixed Allogeneic Chimerism And Renal Allograft Tolerance In Cynomolgus Monkeys , 1995, Transplantation.

[15]  E. Bryant,et al.  USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.

[16]  T. Starzl,et al.  CHIMERISM AND DONOR‐SPECIFIC NONREACTIVITY 27 TO 29 YEARS AFTER KIDNEY ALLOTRANSPLANTATION , 1993, Transplantation.

[17]  H. Deeg,et al.  Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. , 1993, International journal of radiation oncology, biology, physics.

[18]  M. Andreani,et al.  Mixed chimerism in thalassemic patients after bone marrow transplantation. , 1992, Bone marrow transplantation.

[19]  U. Varanasi,et al.  Storage phosphor imaging technique for detection and quantitation of DNA adducts measured by the 32P-postlabeling assay. , 1992, Carcinogenesis.

[20]  D. Danilenko,et al.  Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high-density expression of CD4 by canine neutrophils. , 1992, Tissue antigens.

[21]  T. Starzl,et al.  Cell migration, chimerism, and graft acceptance , 1992, The Lancet.

[22]  D. Sachs,et al.  Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. , 1992, Bone marrow transplantation.

[23]  H. Waldmann,et al.  Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance , 1986, Nature.

[24]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[25]  R. Storb,et al.  Mixed Hematologic Chimerism After Allogeneic Marrow Transplantation for Severe Aplastic Anemia Is Associated With a Higher Risk of Graft Rejection and a Lessened Incidence of Acute Graft-Versus-Host Disease , 1986 .

[26]  H. Deeg,et al.  CYCLOSPORIN A AND METHOTREXATE IN CANINE MARROW TRANSPLANTATION: ENGRAFTMENT, GRAFT‐VERSUS-HOST DISEASE, AND INDUCTION OF TOLERANCE , 1982, Transplantation.

[27]  H. Ochs,et al.  Immunologic Reactivity in Canine Marrow Graft Recipients , 1974, The Journal of Immunology.

[28]  R. Prehn,et al.  Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. , 1955, Journal of the National Cancer Institute.